{
    "SPADE_N_14868": {
        "Sequence Information": {
            "Peptide Name": "Cruzioseptin-16, CZS-16",
            "Sequence": "GFLDVLKGVGKAALGAVTHLINQGEQ",
            "Sequence Length": 26,
            "Biological Activity": [
                "Anti-Gram+",
                "Anti-Gram-",
                "Antiparasitic",
                "Anticancer",
                "Antifungal",
                "Anti-Mammalian Cell"
            ],
            "Binding Target": "1. Lipid Bilayer",
            "Source": "1. Cruziohyla calcarifer",
            "Gene": "",
            "PDB ID": "",
            "UniProt Entry": [],
            "Literature": [
                {
                    "Title": "Novel antimicrobial cruzioseptin peptides extracted from the splendid leaf frog, Cruziohyla calcarifer.",
                    "Pubmed ID": "33942149",
                    "Reference": "Amino Acids. 2021;53:853-868",
                    "Author": "Cuesta SA, Reinoso C, Morales F, Pilaquinga F, Morán-Marcillo G, Proaño-Bolaños C, Blasco-Zuniga A, Rivera M, Meneses L",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/33942149"
                },
                {
                    "Title": "Bioactivity of synthetic peptides from Ecuadorian frog skin secretions against Leishmania mexicana, Plasmodium falciparum, and Trypanosoma cruzi",
                    "Pubmed ID": "39012112",
                    "Reference": "Microbiol Spectr. 2024;:e0333923",
                    "Author": "Proaño-Bolaños C, Morán-Marcillo G, Espinosa de Los Monteros-Silva N, Bermúdez-Puga S, Salazar MA, Blasco-Zúñiga A, Cuesta SA, et al.",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/39012112"
                }
            ],
            "Mass": 2636.01,
            "PI": 6.75,
            "Net Charge": 1,
            "Hydrophobicity": 0.36,
            "Frequent Amino Acids": "GLA",
            "Absent Amino Acids": "CMOPRSUWY",
            "Basic Residues": 3,
            "Acidic Residues": 2,
            "Hydrophobic Residues": 12,
            "Polar Residues": 14,
            "Positive Residues": 3,
            "Negative Residues": 2,
            "SPADE ID": "SPADE_N_14868",
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_N_13707",
                    "Similarity": 1.0,
                    "Sequence": "GFLDVLKGVGKAALGAVTHLINQ"
                },
                {
                    "SPADE_ID": "SPADE_N_14869",
                    "Similarity": 0.9615384615384616,
                    "Sequence": "GFLDVVKGVGKAALGAVTHLINQGEQ"
                },
                {
                    "SPADE_ID": "SPADE_N_13708",
                    "Similarity": 0.9565217391304348,
                    "Sequence": "GFLDVVKGVGKAALGAVTHLINQ"
                }
            ],
            "Hemolytic Activity": "Human erythrocytes:9.7% Hemolysis=55.1 µM,Human erythrocytes:21.8% Hemolysis=110.3 µM,Human erythrocytes:55.2% Hemolysis=220.6 µM,Monkey kidney epithelial cells LLC-MK2:IC50=5.59 µM",
            "Target Organism": "Escherichia coli(MIC=27.5µM),Escherichia coli(MBC=220.6µM),Staphylococcus aureus(MIC=27.5µM),Staphylococcus aureus(MBC=220.6µM),Candida albicans(MIC=55.1µM),Candida albicans(MBC=220.6µM),Leishmania mexicana M379(IC50=6.46µM),Plasmodium falciparum NF54(IC50=36.82µM),Plasmodium falciparum TM90C2B(IC50=34.41µM),Trypanosoma cruzi Tula β-gal(IC50=18.7µM),Trypanosoma cruzi Tula β-gal(IC50=38.33µM),Murine macrophage cells RAW 264.7(IC50=4.40µM)"
        }
    }
}